Starting aspirin therapy after operation: Effects on early graft patency

Steven Goldman, Jack Copeland, Thomas Moritz, William Henderson, Karen Zadina, Theron Ovitt, Karl B Kern, Gulshan Sethi, G. V R K Sharma, Shukri Khuri, Kent Richards, Fred Grover, Douglass Morrison, Glenn Whitman, Elliot Chesler, Y. Sako, Ivan Pacold, Alvaro Montoya, Henry DeMots, Storm FlotenJames Doherty, Raymond Read, Stewart Scott, Ted Spooner, Zaki Masud, Clair Haakenson, Laurence A. Harker

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Background. Although aspirin therapy started before operation improves vein graft patency after coronary artery bypass grafting, it also causes bleeding. The objective of this prospective, centrally directed, randomized, double-blind, placebo-controlled trial was to compare the effects of aspirin therapy started before operation with aspirin started 6 hours after operation on early (7-10-day) graft patency. Methods and Results. Patients were randomized to receive either aspirin 325 mg or placebo the night before surgery; after operation, all patients received aspirin 325 mg daily, with the first dose administered through the nasogastric tube 6 hours after operation. Angiography was performed in 72% of the analyzed patients an average of 8 days after operation, and the primary end point was saphenous vein graft patency in 351 patients. Internal mammary artery graft patency was also assessed in 246 patients because many individuals received both internal mammary artery and vein grafts. In the patients given preoperative aspirin, the vein graft occlusion rate was 7.4±1.3% compared with 7.8±1.5% in those who received preoperative placebo (p=0.871). In the subgroup of patients receiving Y grafts, 0.0% of the grafts were occluded in the preoperative aspirin group compared with 7.0±3.6% in the preoperative placebo group (p=0.066). The internal mammary artery occlusion rate was 0.0% (0 of 131) in the aspirin group compared with 2.4±1.4% (three of 125) in the placebo group (p=0.081). Patients in the aspirin group received more transfusions than those in the placebo group (median, 900 versus 725 ml, p=0.006). The reoperation rate for bleeding in the aspirin group was 6.3% compared with 2.4% in the placebo group (p=0.036). Median chest tube drainage within the first 6 hours after operation was 500 ml in the aspirin group compared with 448 ml in the placebo group (p=0.011). Conclusions. Thus, preoperative aspirin is associated with increased bleeding complications and offers no additional benefit in early vein graft patency compared with starting aspirin therapy 6 hours after operation. There was a trend, although not significant, toward improved early patency for Y grafts and internal mammary artery grafts with preoperative aspirin.

Original languageEnglish (US)
Pages (from-to)520-526
Number of pages7
JournalCirculation
Volume84
Issue number2
StatePublished - Aug 1991
Externally publishedYes

Fingerprint

Aspirin
Transplants
Placebos
Mammary Arteries
Therapeutics
Veins
Hemorrhage
Chest Tubes
Saphenous Vein
Reoperation
Coronary Artery Bypass
Drainage
Angiography

Keywords

  • Antiplatelet therapy
  • Coronary artery bypass graft surgery
  • Graft, vein
  • Internal mammary artery

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Goldman, S., Copeland, J., Moritz, T., Henderson, W., Zadina, K., Ovitt, T., ... Harker, L. A. (1991). Starting aspirin therapy after operation: Effects on early graft patency. Circulation, 84(2), 520-526.

Starting aspirin therapy after operation : Effects on early graft patency. / Goldman, Steven; Copeland, Jack; Moritz, Thomas; Henderson, William; Zadina, Karen; Ovitt, Theron; Kern, Karl B; Sethi, Gulshan; Sharma, G. V R K; Khuri, Shukri; Richards, Kent; Grover, Fred; Morrison, Douglass; Whitman, Glenn; Chesler, Elliot; Sako, Y.; Pacold, Ivan; Montoya, Alvaro; DeMots, Henry; Floten, Storm; Doherty, James; Read, Raymond; Scott, Stewart; Spooner, Ted; Masud, Zaki; Haakenson, Clair; Harker, Laurence A.

In: Circulation, Vol. 84, No. 2, 08.1991, p. 520-526.

Research output: Contribution to journalArticle

Goldman, S, Copeland, J, Moritz, T, Henderson, W, Zadina, K, Ovitt, T, Kern, KB, Sethi, G, Sharma, GVRK, Khuri, S, Richards, K, Grover, F, Morrison, D, Whitman, G, Chesler, E, Sako, Y, Pacold, I, Montoya, A, DeMots, H, Floten, S, Doherty, J, Read, R, Scott, S, Spooner, T, Masud, Z, Haakenson, C & Harker, LA 1991, 'Starting aspirin therapy after operation: Effects on early graft patency', Circulation, vol. 84, no. 2, pp. 520-526.
Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T et al. Starting aspirin therapy after operation: Effects on early graft patency. Circulation. 1991 Aug;84(2):520-526.
Goldman, Steven ; Copeland, Jack ; Moritz, Thomas ; Henderson, William ; Zadina, Karen ; Ovitt, Theron ; Kern, Karl B ; Sethi, Gulshan ; Sharma, G. V R K ; Khuri, Shukri ; Richards, Kent ; Grover, Fred ; Morrison, Douglass ; Whitman, Glenn ; Chesler, Elliot ; Sako, Y. ; Pacold, Ivan ; Montoya, Alvaro ; DeMots, Henry ; Floten, Storm ; Doherty, James ; Read, Raymond ; Scott, Stewart ; Spooner, Ted ; Masud, Zaki ; Haakenson, Clair ; Harker, Laurence A. / Starting aspirin therapy after operation : Effects on early graft patency. In: Circulation. 1991 ; Vol. 84, No. 2. pp. 520-526.
@article{8524c4dffe294a79b0bdd51e0bfdc6e2,
title = "Starting aspirin therapy after operation: Effects on early graft patency",
abstract = "Background. Although aspirin therapy started before operation improves vein graft patency after coronary artery bypass grafting, it also causes bleeding. The objective of this prospective, centrally directed, randomized, double-blind, placebo-controlled trial was to compare the effects of aspirin therapy started before operation with aspirin started 6 hours after operation on early (7-10-day) graft patency. Methods and Results. Patients were randomized to receive either aspirin 325 mg or placebo the night before surgery; after operation, all patients received aspirin 325 mg daily, with the first dose administered through the nasogastric tube 6 hours after operation. Angiography was performed in 72{\%} of the analyzed patients an average of 8 days after operation, and the primary end point was saphenous vein graft patency in 351 patients. Internal mammary artery graft patency was also assessed in 246 patients because many individuals received both internal mammary artery and vein grafts. In the patients given preoperative aspirin, the vein graft occlusion rate was 7.4±1.3{\%} compared with 7.8±1.5{\%} in those who received preoperative placebo (p=0.871). In the subgroup of patients receiving Y grafts, 0.0{\%} of the grafts were occluded in the preoperative aspirin group compared with 7.0±3.6{\%} in the preoperative placebo group (p=0.066). The internal mammary artery occlusion rate was 0.0{\%} (0 of 131) in the aspirin group compared with 2.4±1.4{\%} (three of 125) in the placebo group (p=0.081). Patients in the aspirin group received more transfusions than those in the placebo group (median, 900 versus 725 ml, p=0.006). The reoperation rate for bleeding in the aspirin group was 6.3{\%} compared with 2.4{\%} in the placebo group (p=0.036). Median chest tube drainage within the first 6 hours after operation was 500 ml in the aspirin group compared with 448 ml in the placebo group (p=0.011). Conclusions. Thus, preoperative aspirin is associated with increased bleeding complications and offers no additional benefit in early vein graft patency compared with starting aspirin therapy 6 hours after operation. There was a trend, although not significant, toward improved early patency for Y grafts and internal mammary artery grafts with preoperative aspirin.",
keywords = "Antiplatelet therapy, Coronary artery bypass graft surgery, Graft, vein, Internal mammary artery",
author = "Steven Goldman and Jack Copeland and Thomas Moritz and William Henderson and Karen Zadina and Theron Ovitt and Kern, {Karl B} and Gulshan Sethi and Sharma, {G. V R K} and Shukri Khuri and Kent Richards and Fred Grover and Douglass Morrison and Glenn Whitman and Elliot Chesler and Y. Sako and Ivan Pacold and Alvaro Montoya and Henry DeMots and Storm Floten and James Doherty and Raymond Read and Stewart Scott and Ted Spooner and Zaki Masud and Clair Haakenson and Harker, {Laurence A.}",
year = "1991",
month = "8",
language = "English (US)",
volume = "84",
pages = "520--526",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Starting aspirin therapy after operation

T2 - Effects on early graft patency

AU - Goldman, Steven

AU - Copeland, Jack

AU - Moritz, Thomas

AU - Henderson, William

AU - Zadina, Karen

AU - Ovitt, Theron

AU - Kern, Karl B

AU - Sethi, Gulshan

AU - Sharma, G. V R K

AU - Khuri, Shukri

AU - Richards, Kent

AU - Grover, Fred

AU - Morrison, Douglass

AU - Whitman, Glenn

AU - Chesler, Elliot

AU - Sako, Y.

AU - Pacold, Ivan

AU - Montoya, Alvaro

AU - DeMots, Henry

AU - Floten, Storm

AU - Doherty, James

AU - Read, Raymond

AU - Scott, Stewart

AU - Spooner, Ted

AU - Masud, Zaki

AU - Haakenson, Clair

AU - Harker, Laurence A.

PY - 1991/8

Y1 - 1991/8

N2 - Background. Although aspirin therapy started before operation improves vein graft patency after coronary artery bypass grafting, it also causes bleeding. The objective of this prospective, centrally directed, randomized, double-blind, placebo-controlled trial was to compare the effects of aspirin therapy started before operation with aspirin started 6 hours after operation on early (7-10-day) graft patency. Methods and Results. Patients were randomized to receive either aspirin 325 mg or placebo the night before surgery; after operation, all patients received aspirin 325 mg daily, with the first dose administered through the nasogastric tube 6 hours after operation. Angiography was performed in 72% of the analyzed patients an average of 8 days after operation, and the primary end point was saphenous vein graft patency in 351 patients. Internal mammary artery graft patency was also assessed in 246 patients because many individuals received both internal mammary artery and vein grafts. In the patients given preoperative aspirin, the vein graft occlusion rate was 7.4±1.3% compared with 7.8±1.5% in those who received preoperative placebo (p=0.871). In the subgroup of patients receiving Y grafts, 0.0% of the grafts were occluded in the preoperative aspirin group compared with 7.0±3.6% in the preoperative placebo group (p=0.066). The internal mammary artery occlusion rate was 0.0% (0 of 131) in the aspirin group compared with 2.4±1.4% (three of 125) in the placebo group (p=0.081). Patients in the aspirin group received more transfusions than those in the placebo group (median, 900 versus 725 ml, p=0.006). The reoperation rate for bleeding in the aspirin group was 6.3% compared with 2.4% in the placebo group (p=0.036). Median chest tube drainage within the first 6 hours after operation was 500 ml in the aspirin group compared with 448 ml in the placebo group (p=0.011). Conclusions. Thus, preoperative aspirin is associated with increased bleeding complications and offers no additional benefit in early vein graft patency compared with starting aspirin therapy 6 hours after operation. There was a trend, although not significant, toward improved early patency for Y grafts and internal mammary artery grafts with preoperative aspirin.

AB - Background. Although aspirin therapy started before operation improves vein graft patency after coronary artery bypass grafting, it also causes bleeding. The objective of this prospective, centrally directed, randomized, double-blind, placebo-controlled trial was to compare the effects of aspirin therapy started before operation with aspirin started 6 hours after operation on early (7-10-day) graft patency. Methods and Results. Patients were randomized to receive either aspirin 325 mg or placebo the night before surgery; after operation, all patients received aspirin 325 mg daily, with the first dose administered through the nasogastric tube 6 hours after operation. Angiography was performed in 72% of the analyzed patients an average of 8 days after operation, and the primary end point was saphenous vein graft patency in 351 patients. Internal mammary artery graft patency was also assessed in 246 patients because many individuals received both internal mammary artery and vein grafts. In the patients given preoperative aspirin, the vein graft occlusion rate was 7.4±1.3% compared with 7.8±1.5% in those who received preoperative placebo (p=0.871). In the subgroup of patients receiving Y grafts, 0.0% of the grafts were occluded in the preoperative aspirin group compared with 7.0±3.6% in the preoperative placebo group (p=0.066). The internal mammary artery occlusion rate was 0.0% (0 of 131) in the aspirin group compared with 2.4±1.4% (three of 125) in the placebo group (p=0.081). Patients in the aspirin group received more transfusions than those in the placebo group (median, 900 versus 725 ml, p=0.006). The reoperation rate for bleeding in the aspirin group was 6.3% compared with 2.4% in the placebo group (p=0.036). Median chest tube drainage within the first 6 hours after operation was 500 ml in the aspirin group compared with 448 ml in the placebo group (p=0.011). Conclusions. Thus, preoperative aspirin is associated with increased bleeding complications and offers no additional benefit in early vein graft patency compared with starting aspirin therapy 6 hours after operation. There was a trend, although not significant, toward improved early patency for Y grafts and internal mammary artery grafts with preoperative aspirin.

KW - Antiplatelet therapy

KW - Coronary artery bypass graft surgery

KW - Graft, vein

KW - Internal mammary artery

UR - http://www.scopus.com/inward/record.url?scp=0025764641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025764641&partnerID=8YFLogxK

M3 - Article

C2 - 1860197

AN - SCOPUS:0025764641

VL - 84

SP - 520

EP - 526

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -